GlassScriptPhysician profile
Zheng Zhou
NPI 1659531770
$30,414.88
in general payments reported to CMS, 2019-2025
24 companies · $2,152 in 2025
The $2,152 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.93 · 2020: $7,588 · 2021: $6,372 · 2022: $672 · 2023: $7,839 · 2024: $5,767 · 2025: $2,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,602 · Consulting Fee: $6,575 · Food and Beverage: $1,296 · Travel and Lodging: $1,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,602.00 |
| Consulting Fee | $6,575.00 |
| Food and Beverage | $1,296.18 |
| Travel and Lodging | $1,284.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $7,986.29 | 2020-2025 | Ojjaara |
| Incyte Corporation | $5,892.26 | 2023 | Jakafi |
| Beigene USA, INC. | $2,850.00 | 2020-2024 | Brukinsa |
| Agios Pharmaceuticals, INC. | $2,800.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $2,797.50 | 2021-2024 | Imfinzi |
| Adaptive Biotechnologies Corporation | $2,000.00 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $1,170.00 | 2021 | |
| Morphosys, US INC. | $1,140.00 | 2021 | |
| Janssen Biotech, INC. | $1,110.29 | 2020-2024 | Rybrevant |
| Daiichi Sankyo INC. | $650.00 | 2025 | Vanflyta |
| Merck Sharp & Dohme LLC | $643.81 | 2023 | |
| Beigene, LTD. | $525.00 | 2021 | |
| Adc Therapeutics America, INC. | $189.19 | 2021-2023 | |
| Cti Biopharma Corp. | $173.61 | 2023 | Vonjo |
| Novartis Pharmaceuticals Corporation | $139.50 | 2023 | Kymriah |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $105.30 | 2024 | |
| Epizyme, INC. | $99.95 | 2022 | |
| Seagen INC. | $49.95 | 2021 | |
| Pfizer INC. | $47.00 | 2022 | |
| Celgene Corporation | $25.93 | 2019 | |
| Kite Pharma, INC. | $19.30 | 2024 | Yescarta |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zheng Zhou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.